Scott Barry has over 20 years of experience in investment banking and the healthcare industry. He joined Essex Woodlands from Novartis Pharma AG where he most recently served as the Global Head of Pharma M&A and Collaborations. In this role, he was responsible for global acquisitions, equity investments and corporate partnerships across all therapeutic areas. He joined Novartis in 2002 and held positions in the Business Development & Licensing and Mergers & Acquisitions groups. Prior to joining Novartis, Scott was a Director for Century Capital Associates LLC, a boutique healthcare investment bank and consulting firm, where he focused on mergers & acquisitions, strategic partnering and financing transactions. Previously, he held positions at KPMG LLP in their healthcare corporate finance and assurance services groups.
Scott previously served on the Board of Directors of Orthovita, Inc. (NASDAQ: VITA) which was acquired by Stryker Corporation, and Victory Pharma, Inc., which was acquired by Shionogi, Inc. and Velcera, which was acquired by Perrigo Company. Scott currently serves on the Board of Directors for the United Orthopedic Group. He is also an observer for the board of ZIOPHARM Oncology, Inc. and Bioventus.
Scott graduated with a Bachelor of Arts degree from Wesleyan University and a Master of Business Administration degree from New York University.
Scott joined Essex Woodlands as Principal in the New York office in October 2006, was promoted to Partner in 2008, and was promoted to Managing Director and co-head of the Shanghai office in June 2012.